UBS analyst Kavya Deshpande initiated coverage of Elekta (EKTAY) with a Sell rating and SEK 34 price target The firm’s analysis suggests the radiotherapy market is slowing meaningfully and that Elekta is unlikely to compensate with share gains.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EKTAY: